ARNA stronger, HBAN volume leader, RXII tumbles

Arena Pharmaceuticals, Inc. (Nasdaq: ARNA) pushed upward 23.64 percent in price Monday to $2.04. Volume of 14,985,720 shares nearly doubled its full-day average. The San Diego-based ARNA is a clinical-stage biopharmaceutical company focused on discovering, developing and commercializing oral drugs that target G protein-coupled receptors.

Huntington Bancshares Inc. (Nasdaq: HBAN) traded in 27,626,739 shares, bested its daily average by a half. Share prices for HBAN moved moderately ahead 4.98 percent to $6.54. Columbus-based HBAN is a $53-billion regional bank holding company

RXi Pharmaceuticals Corp. (Nasdaq: RXII) stumbled in price 11.43 percent Monday to $2.79, on volume of 705,157 shares, nearly quadrupled its full-day average. RXII is a recognized leader in RNAi-based therapeutic discovery and development

Tags: arna, biopharmaceuticals, Financial Stocks, HBAN, healthcare, nasdaq, pharmaceutical stocks, RXII

This entry was posted on Monday, December 20th, 2010 at 2:28 pm by Glenn and is filed under Financial Stocks, Health Care Stocks. You can follow any responses to this entry through the RSS 2.0 feed. You can leave a response, or trackback from your own site.